Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial.

Lyubarova R, Albers JJ, Marcovina SM, Yao Y, McBride R, Topliceanu A, Anderson T, Fleg JL, Desvigne-Nickens P, Kashyap ML, McGovern ME, Boden WE.

J Cardiovasc Pharmacol Ther. 2019 May 26:1074248419852955. doi: 10.1177/1074248419852955. [Epub ahead of print]

PMID:
31131629
2.

Association of Serum Paraoxonase/Arylesterase Activity with All-Cause Mortality in Maintenance Hemodialysis Patients.

Suematsu Y, Goto M, Park C, Nunes ACF, Jing W, Streja E, Rhee CM, Cruz S, Kashyap ML, Vaziri ND, Narayanaswami V, Kalantar-Zadeh K, Moradi H.

J Clin Endocrinol Metab. 2019 Mar 28. pii: jc.2019-00334. doi: 10.1210/jc.2019-00334. [Epub ahead of print]

PMID:
30920627
3.

Statin Therapy Before Transition to End-Stage Renal Disease With Posttransition Outcomes.

Soohoo M, Moradi H, Obi Y, Rhee CM, Gosmanova EO, Molnar MZ, Kashyap ML, Gillen DL, Kovesdy CP, Kalantar-Zadeh K, Streja E.

J Am Heart Assoc. 2019 Mar 19;8(6):e011869. doi: 10.1161/JAHA.118.011869.

4.

Inverse Association Between Serum Non-High-Density Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis.

Chang TI, Streja E, Ko GJ, Naderi N, Rhee CM, Kovesdy CP, Kashyap ML, Vaziri ND, Kalantar-Zadeh K, Moradi H.

J Am Heart Assoc. 2018 Jun 9;7(12). pii: e009096. doi: 10.1161/JAHA.118.009096.

5.

Increments in serum high-density lipoprotein cholesterol over time are not associated with improved outcomes in incident hemodialysis patients.

Chang TI, Streja E, Soohoo M, Ko GJ, Rhee CM, Kovesdy CP, Kashyap ML, Vaziri ND, Kalantar-Zadeh K, Moradi H.

J Clin Lipidol. 2018 Mar - Apr;12(2):488-497. doi: 10.1016/j.jacl.2018.01.010. Epub 2018 Jan 31.

6.

LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.

Suematsu Y, Jing W, Nunes A, Kashyap ML, Khazaeli M, Vaziri ND, Moradi H.

J Card Fail. 2018 Apr;24(4):266-275. doi: 10.1016/j.cardfail.2017.12.010. Epub 2018 Jan 8.

7.

Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients.

Chang TI, Streja E, Soohoo M, Kim TW, Rhee CM, Kovesdy CP, Kashyap ML, Vaziri ND, Kalantar-Zadeh K, Moradi H.

Clin J Am Soc Nephrol. 2017 Apr 3;12(4):591-602. doi: 10.2215/CJN.08730816. Epub 2017 Feb 13.

8.

Association of serum lipids with outcomes in Hispanic hemodialysis patients of the West versus East Coasts of the United States.

Moradi H, Abhari P, Streja E, Kashyap ML, Shah G, Gillen D, Pahl MV, Vaziri ND, Kalantar-Zadeh K.

Am J Nephrol. 2015;41(4-5):284-95. doi: 10.1159/000381991. Epub 2015 May 30.

9.

Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease.

Ganji SH, Kashyap ML, Kamanna VS.

Metabolism. 2015 Sep;64(9):982-90. doi: 10.1016/j.metabol.2015.05.002. Epub 2015 May 7.

PMID:
26024755
10.

Niacin and progression of CKD.

Streja E, Kovesdy CP, Streja DA, Moradi H, Kalantar-Zadeh K, Kashyap ML.

Am J Kidney Dis. 2015 May;65(5):785-98. doi: 10.1053/j.ajkd.2014.11.033. Epub 2015 Feb 21. Review.

PMID:
25708553
11.

Safety profile of extended-release niacin in the AIM-HIGH trial.

Anderson TJ, Boden WE, Desvigne-Nickens P, Fleg JL, Kashyap ML, McBride R, Probstfield JL; AIM-HIGH Investigators.

N Engl J Med. 2014 Jul 17;371(3):288-90. doi: 10.1056/NEJMc1311039. No abstract available.

12.

Niacin decreases leukocyte myeloperoxidase: mechanistic role of redox agents and Src/p38MAP kinase.

Ganji SH, Kamanna VS, Kashyap ML.

Atherosclerosis. 2014 Aug;235(2):554-61. doi: 10.1016/j.atherosclerosis.2014.05.948. Epub 2014 Jun 6.

PMID:
24956528
13.

Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients.

Moradi H, Streja E, Kashyap ML, Vaziri ND, Fonarow GC, Kalantar-Zadeh K.

Nephrol Dial Transplant. 2014 Aug;29(8):1554-62. doi: 10.1093/ndt/gfu022. Epub 2014 Feb 25.

14.

Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.

Ganji SH, Kukes GD, Lambrecht N, Kashyap ML, Kamanna VS.

Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G320-7. doi: 10.1152/ajpgi.00181.2013. Epub 2013 Dec 19.

15.

Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).

Albers JJ, Slee A, O'Brien KD, Robinson JG, Kashyap ML, Kwiterovich PO Jr, Xu P, Marcovina SM.

J Am Coll Cardiol. 2013 Oct 22;62(17):1575-9. doi: 10.1016/j.jacc.2013.06.051. Epub 2013 Aug 21.

16.

Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).

Guyton JR, Slee AE, Anderson T, Fleg JL, Goldberg RB, Kashyap ML, Marcovina SM, Nash SD, O'Brien KD, Weintraub WS, Xu P, Zhao XQ, Boden WE.

J Am Coll Cardiol. 2013 Oct 22;62(17):1580-4. doi: 10.1016/j.jacc.2013.07.023. Epub 2013 Jul 31.

17.

Mammalian colonocytes possess a carrier-mediated mechanism for uptake of vitamin B3 (niacin): studies utilizing human and mouse colonic preparations.

Kumar JS, Subramanian VS, Kapadia R, Kashyap ML, Said HM.

Am J Physiol Gastrointest Liver Physiol. 2013 Aug 1;305(3):G207-13. doi: 10.1152/ajpgi.00148.2013. Epub 2013 Jun 6.

18.

Recent advances in niacin and lipid metabolism.

Kamanna VS, Ganji SH, Kashyap ML.

Curr Opin Lipidol. 2013 Jun;24(3):239-45. doi: 10.1097/MOL.0b013e3283613a68. Review.

PMID:
23619367
19.

Role of HDL dysfunction in end-stage renal disease: a double-edged sword.

Moradi H, Vaziri ND, Kashyap ML, Said HM, Kalantar-Zadeh K.

J Ren Nutr. 2013 May;23(3):203-6. doi: 10.1053/j.jrn.2013.01.022. Review.

20.

Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells.

Zhang LH, Kamanna VS, Ganji SH, Xiong XM, Kashyap ML.

J Lipid Res. 2012 May;53(5):941-50. doi: 10.1194/jlr.M020917. Epub 2012 Mar 1.

21.

Reverse D4F, an apolipoprotein-AI mimetic peptide, inhibits atherosclerosis in ApoE-null mice.

Qin S, Kamanna VS, Lai JH, Liu T, Ganji SH, Zhang L, Bachovchin WW, Kashyap ML.

J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):334-43. doi: 10.1177/1074248411434598. Epub 2012 Feb 3.

PMID:
22308547
22.

Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.

Brinton EA, Kashyap ML, Vo AN, Thakkar RB, Jiang P, Padley RJ.

Am J Cardiovasc Drugs. 2011 Jun 1;11(3):179-87. doi: 10.2165/11592560-000000000-00000.

PMID:
21619381
23.

Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells.

Zhang LH, Kamanna VS, Ganji SH, Xiong XM, Kashyap ML.

J Lipid Res. 2010 Aug;51(8):2211-22. doi: 10.1194/jlr.M004481. Epub 2010 Apr 6.

24.

The mechanism and mitigation of niacin-induced flushing.

Kamanna VS, Ganji SH, Kashyap ML.

Int J Clin Pract. 2009 Sep;63(9):1369-77. doi: 10.1111/j.1742-1241.2009.02099.x. Review.

25.

Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.

Thakkar RB, Kashyap ML, Lewin AJ, Krause SL, Jiang P, Padley RJ.

Am J Cardiovasc Drugs. 2009;9(2):69-79. doi: 10.2165/00129784-200909020-00001.

PMID:
19331435
26.

Niacin: an old drug rejuvenated.

Kamanna VS, Ganji SH, Kashyap ML.

Curr Atheroscler Rep. 2009 Jan;11(1):45-51. Review.

PMID:
19080727
27.

Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.

Vo AN, Kashyap ML.

Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1303-10. doi: 10.1586/14779072.6.10.1303. Review.

PMID:
19018682
28.

Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.

Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.

Atherosclerosis. 2009 May;204(1):208-15. doi: 10.1016/j.atherosclerosis.2008.09.027. Epub 2008 Oct 5.

PMID:
18996523
29.

Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells.

Qin S, Koga T, Ganji SH, Kamanna VS, Kashyap ML.

Metabolism. 2008 Jul;57(7):973-9. doi: 10.1016/j.metabol.2008.02.014.

PMID:
18555840
30.

Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells.

Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML.

Atherosclerosis. 2009 Jan;202(1):68-75. doi: 10.1016/j.atherosclerosis.2008.04.044. Epub 2008 May 9.

PMID:
18550065
31.

Mechanism of action of niacin.

Kamanna VS, Kashyap ML.

Am J Cardiol. 2008 Apr 17;101(8A):20B-26B. doi: 10.1016/j.amjcard.2008.02.029. Review.

PMID:
18375237
32.

Nicotinic acid: recent developments.

Kamanna VS, Vo A, Kashyap ML.

Curr Opin Cardiol. 2008 Jul;23(4):393-8. doi: 10.1097/HCO.0b013e3283021c82. Review.

PMID:
18520725
33.

Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.

Karas RH, Kashyap ML, Knopp RH, Keller LH, Bajorunas DR, Davidson MH.

Am J Cardiovasc Drugs. 2008;8(2):69-81.

PMID:
18422390
34.

Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL.

Zhang LH, Kamanna VS, Zhang MC, Kashyap ML.

J Lipid Res. 2008 Jun;49(6):1195-201. doi: 10.1194/jlr.M700426-JLR200. Epub 2008 Mar 3.

35.

Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?

Kamanna VS, Kashyap ML.

Am J Cardiol. 2007 Dec 3;100(11 A):S53-61. Review.

PMID:
18047854
36.

Mechanism of nicotinic acid transport in human liver cells: experiments with HepG2 cells and primary hepatocytes.

Said HM, Nabokina SM, Balamurugan K, Mohammed ZM, Urbina C, Kashyap ML.

Am J Physiol Cell Physiol. 2007 Dec;293(6):C1773-8. Epub 2007 Oct 10.

37.

Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha.

Qin S, Liu T, Kamanna VS, Kashyap ML.

Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2428-34. Epub 2007 Sep 13.

PMID:
17872455
38.

Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).

McKenney JM, Jones PH, Bays HE, Knopp RH, Kashyap ML, Ruoff GE, McGovern ME.

Atherosclerosis. 2007 Jun;192(2):432-7. Epub 2007 Jan 19.

PMID:
17239888
39.

Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush.

Meyers CD, Liu P, Kamanna VS, Kashyap ML.

Atherosclerosis. 2007 Jun;192(2):253-8. Epub 2006 Sep 1.

PMID:
16945375
40.

Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial).

Meyers CD, McCarren M, Wong ND, Abraira C, Duckworth WC, Kashyap ML; VADT Investigators.

Am J Cardiol. 2006 Jul 1;98(1):63-5. Epub 2006 May 4.

PMID:
16784922
41.

Anticipating the evolution of clinical cholesterol guidelines: implications of recent statin intervention trials.

Meyers CD, Wong N, Kashyap ML.

Future Cardiol. 2005 Jul;1(4):461-71. doi: 10.2217/14796678.1.4.461.

PMID:
19804146
42.

Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies.

Meyers CD, Kashyap ML.

Curr Opin Cardiol. 2005 Jul;20(4):307-12. Review.

PMID:
15956828
43.

Mechanism and regulation of human intestinal niacin uptake.

Nabokina SM, Kashyap ML, Said HM.

Am J Physiol Cell Physiol. 2005 Jul;289(1):C97-103. Epub 2005 Feb 23.

44.

Pharmacologic treatment of type 2 diabetic dyslipidemia.

Moon YS, Kashyap ML.

Pharmacotherapy. 2004 Dec;24(12):1692-713. Review.

PMID:
15585439
45.

Niacin therapy in atherosclerosis.

Meyers CD, Kamanna VS, Kashyap ML.

Curr Opin Lipidol. 2004 Dec;15(6):659-65. Review.

PMID:
15529025
46.

Management of the metabolic syndrome-nicotinic acid.

Meyers CD, Kashyap ML.

Endocrinol Metab Clin North Am. 2004 Sep;33(3):557-75, vii. Review.

PMID:
15262297
47.

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells.

Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML.

J Lipid Res. 2004 Oct;45(10):1835-45. Epub 2004 Jul 16.

48.
49.

Dyslipidemia treatment: current considerations and unmet needs.

Malik S, Kashyap ML.

Expert Rev Cardiovasc Ther. 2003 May;1(1):121-34. Review.

PMID:
15030302
50.

Optimal therapy of low levels of high density lipoprotein-cholesterol.

Kashyap ML, Tavintharan S, Kamanna VS.

Am J Cardiovasc Drugs. 2003;3(1):53-65. Review.

PMID:
14727946

Supplemental Content

Loading ...
Support Center